Amneal Pharmaceuticals shares rose 5.7% after UBS initiated coverage with a Buy rating and a $19 price target. UBS highlighted Amneal's specialty pharma segment, especially Parkinson's treatments Crexont and Rytary, as key growth drivers with a forecasted 6% CAGR through 2030. UBS expects Amneal to achieve a 7% five-year revenue CAGR and 15% EPS growth, above consensus, supported by product mix, operating leverage, and pipeline opportunities like Brekiya and a GLP-1 manufacturing partnership. The firm also noted Amneal's exposure to a large market from $80 billion in upcoming drug patent expiries, with a 9% CAGR expected in its Affordable Medicines segment through 2030.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
